The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Good Flow: 2021 Updates in Vasculitis

Good Flow: 2021 Updates in Vasculitis

December 6, 2021 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR Convergence 2021—The world of vasculitis has seen several significant changes over the past year, and these important advances were discussed by Peter Merkel, MD, MPH, chief, Division of Rheumatology, University of Pennsylvania, Philadelphia, during the ACR Convergence 2021 annual Review Course.

You Might Also Like
  • ANCA-Associated Vasculitis Trial Results May Change Standard of Care
  • Study Probes Whether Belimumab Can Lower Vasculitis Relapse Rate
  • ANCA-Associated Vasculitis Pathogenesis & Treatment Updates
Also By This Author
  • From Strength to Strength: Idiopathic Inflammatory Myopathy Diagnosis & Management

Dr. Merkel began by noting that the ACR and Vasculitis Foundation worked together to publish guidelines this year for several forms of systemic vasculitis. Among these guidelines was a document dedicated to anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, which can come in the form of granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) or eosinophilic granulomatosis with polyangiitis (EGPA).

Dr. Merkel

Dr. Merkel

Treatments

Dr. Merkel noted that for non-severe ANCA-associated vasculitis (i.e., not organ- or life-threatening), methotrexate and rituximab both represent reasonable agents for induction of remission; maintenance medications can include methotrexate, azathioprine, rituximab or—as a third-line option—mycophenolate mofetil.

For severe disease, cyclophosphamide remains an option for induction of remission, but it is being used less and less in the U.S., given the efficacy demonstrated by rituximab and the significant toxicities that can occur with cyclophosphamide treatment.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Avacopan may now help fulfill an unmet clinical need to reduce or avoid glucocorticoids while yielding better long-term outcomes for patients.

Remission Maintenance

Concerning maintenance of remission in ANCA-associated vasculitis, the MAINRITSAN-1 trial found that 500 mg of rituximab every six months is more effective than 2 mg/kg/day of azathioprine for remission maintenance.2

Dr. Merkel did point out several questions that remained after this trial was completed, including: What would the effects of a higher dose of rituximab have been? Because all patients in this study received cyclophosphamide for induction, what is the generalizability to patients who do not receive this agent for induction treatment? What would have been the results if azathioprine had not been tapered from the 2 mg/kg/day dose after one year?

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Merkel also discussed the RITAZAREM trial, for which he is a co-primary investigator. This is a study of 190 patients with GPA or MPA with relapse treated with rituximab at a dose of 375 mg/m2 intravenous (IV) infusion weekly for four consecutive weeks. Patients who were then in remission at four months were randomized to either rituximab 1g IV every four months or azathioprine 2 mg/kg/day from months 4 to 24.

Dr. Merkel et al. found that rituximab was superior to azathioprine for preventing disease relapse, but he did point out in his talk that the rate of relapse accelerated in both arms once either agent (rituximab or azathioprine) was stopped at 24 months.3

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Guidelines, Meeting Reports, Vasculitis Tagged With: ACR Convergence 2021

You Might Also Like:
  • ANCA-Associated Vasculitis Trial Results May Change Standard of Care
  • Study Probes Whether Belimumab Can Lower Vasculitis Relapse Rate
  • ANCA-Associated Vasculitis Pathogenesis & Treatment Updates
  • How Do Reduced-Dose Glucocorticoids Plus Rituximab Affect ANCA-Associated Vasculitis?

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)